New vaccine aims to shield seniors from pneumococcal disease
NCT ID NCT07712575
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests an experimental vaccine called V132 in healthy adults aged 50 and older. The goal is to see how safe it is and how well it triggers an immune response compared to existing pneumococcal vaccines. Participants will receive one of several formulations of V132 or a comparator vaccine, and researchers will monitor for side effects and measure antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental pneumococcal vaccine called V132
- What this could lead to
- If successful, V132 could provide better protection against pneumococcal disease for older adults, who are at higher risk.
- What could go wrong
- This is an early Phase 1 trial focused on safety and immune response, so it is too soon to know if V132 will be effective or have significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Which medical adhesive stays put longest without itching? a head-to-head test in healthy women.
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- New eye drop aims to tame ocular pain in early trial
- Could a formula closer to breast milk boost baby development?
- Could a daily probiotic help you feel fuller and eat less?